Gt Biopharma Stock Performance
GTBP Stock | USD 3.65 0.13 3.44% |
The company owns a Beta (Systematic Risk) of -1.21, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning GT Biopharma are expected to decrease by larger amounts. On the other hand, during market turmoil, GT Biopharma is expected to outperform it. GT Biopharma has an expected return of -0.7%. Please make sure to check out GT Biopharma potential upside, and the relationship between the jensen alpha and rate of daily change , to decide if GT Biopharma performance from the past will be repeated sooner or later.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days GT Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's fundamental drivers remain relatively invariable which may send shares a bit higher in May 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Actual Historical Performance (%)
One Day Return 4.79 | Five Day Return (1.27) | Year To Date Return (50.96) | Ten Year Return (100.00) | All Time Return (100.00) |
Last Split Factor 1:30 | Dividend Date 2017-08-21 | Last Split Date 2024-02-05 |
1 | GT Biopharma announces 1-for-30 reverse stock split | 02/01/2024 |
2 | GT Biopharma Inc Annual Shareholders Meeting Transcript - GuruFocus.com | 02/06/2024 |
3 | Disposition of 50000 shares by Steven Weldon of GT Biopharma at 0.33 subject to Rule 16b-3 | 03/18/2024 |
4 | GTBP Stock Earnings GT Biopharma Beats EPS for Q4 2023 | 03/27/2024 |
5 | Insider Trading | 04/18/2024 |
Begin Period Cash Flow | 5.7 M |
GTBP |
GT Biopharma Relative Risk vs. Return Landscape
If you would invest 633.00 in GT Biopharma on January 26, 2024 and sell it today you would lose (268.00) from holding GT Biopharma or give up 42.34% of portfolio value over 90 days. GT Biopharma is currently does not generate positive expected returns and assumes 6.0435% risk (volatility on return distribution) over the 90 days horizon. In different words, 53% of stocks are less volatile than GTBP, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
GT Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for GT Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as GT Biopharma, and traders can use it to determine the average amount a GT Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1166
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | GTBP |
Estimated Market Risk
6.04 actual daily | 53 53% of assets are less volatile |
Expected Return
-0.7 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.12 actual daily | 0 Most of other assets perform better |
Based on monthly moving average GT Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of GT Biopharma by adding GT Biopharma to a well-diversified portfolio.
GT Biopharma Fundamentals Growth
GTBP Stock prices reflect investors' perceptions of the future prospects and financial health of GT Biopharma, and GT Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on GTBP Stock performance.
Return On Equity | -0.79 | ||||
Return On Asset | -0.55 | ||||
Current Valuation | (8.87 M) | ||||
Shares Outstanding | 1.38 M | ||||
Price To Book | 0.72 X | ||||
EBITDA | (13.58 M) | ||||
Net Income | (7.6 M) | ||||
Cash And Equivalents | 23.73 M | ||||
Cash Per Share | 0.76 X | ||||
Total Debt | 58 K | ||||
Debt To Equity | 0.01 % | ||||
Current Ratio | 2.78 X | ||||
Book Value Per Share | 5.41 X | ||||
Cash Flow From Operations | (8.85 M) | ||||
Earnings Per Share | (5.58) X | ||||
Market Capitalization | 5.04 M | ||||
Total Asset | 14.11 M | ||||
Retained Earnings | (682.07 M) | ||||
Working Capital | 7.42 M | ||||
About GT Biopharma Performance
To evaluate GT Biopharma Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when GT Biopharma generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare GTBP Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand GT Biopharma market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents GTBP's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Last Reported | Projected for Next Year | ||
Days Of Inventory On Hand | 61.05 | 86.22 | |
Return On Tangible Assets | (0.54) | (0.57) | |
Return On Capital Employed | (1.82) | (1.91) | |
Return On Assets | (0.54) | (0.51) | |
Return On Equity | (1.02) | (1.07) |
Things to note about GT Biopharma performance evaluation
Checking the ongoing alerts about GT Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for GT Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.GT Biopharma generated a negative expected return over the last 90 days | |
GT Biopharma has high historical volatility and very poor performance | |
GT Biopharma has a very high chance of going through financial distress in the upcoming years | |
Net Loss for the year was (7.6 M) with profit before overhead, payroll, taxes, and interest of 0. | |
GT Biopharma currently holds about 23.73 M in cash with (8.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76. | |
Latest headline from MacroaxisInsider: Insider Trading |
- Analyzing GT Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether GT Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining GT Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating GT Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of GT Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of GT Biopharma's stock. These opinions can provide insight into GT Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GT Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in GTBP Stock, please use our How to Invest in GT Biopharma guide.Note that the GT Biopharma information on this page should be used as a complementary analysis to other GT Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for GTBP Stock analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |
Is GT Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GT Biopharma. If investors know GTBP will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GT Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.58) | Return On Assets (0.55) | Return On Equity (0.79) |
The market value of GT Biopharma is measured differently than its book value, which is the value of GTBP that is recorded on the company's balance sheet. Investors also form their own opinion of GT Biopharma's value that differs from its market value or its book value, called intrinsic value, which is GT Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GT Biopharma's market value can be influenced by many factors that don't directly affect GT Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GT Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if GT Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GT Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.